Pharmaceutical Technology, May 2, 2007 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe
Pharmaceutical Technology, May 2, 2007
Articles
Advancing the Peptide Pipeline
By Patricia Van Arnum
The pharmaceutical majors build their capabilities in peptide technology, and contract manufacturers expand to meet growing demand for bulk peptides.
Review of Current Issues in Pharmaceutical Excipients
By Dorothy Chang , Rong-Kun Chang
Excipients facilitate formulation design and perform a wide range of functions to obtain desired properties for the finished drug product. The article reviews excipient development and functionality of these materials, including their importance in formulation design, potential processing challenges directly related to excipients, and therapeutic benefits.
Eluting Possibilities with Mixed-Mode Chromatography
By Maribel Rios
Mixed-mode chromatography sorbents and custom ligands aim to optimize protein purification.
Inside USP
Dissolution Testing and Metrological Measurement of Quality for Solid Oral Dosage Forms
By Ronald G. Manning, PhD , Samir Z. Wahab, PhD , William E. Brown , Walter W. Hauck, PhD , Stefan Schuber, PhD , Roger L. Williams
USP applies metrological principles to the dissolution procedure alone and in collaborative studies to understand and minimize potential sources of variability.
Outsourcing
Functional versus Full-Service Outsourcing Models
By Jim Miller
Preferred models for clinical and nonclinical services move in opposite directions.
Washington Report
FDA Seeks Streamlined, More Effective GMP Inspections
By Jill Wechsler
Fewer field offices and inspectors will increase reliance on manufacturers to ensure product and process quality.
Viewpoint
Pharmaceutical Benchmarking: A Contract-Manufacturing Perspective
By Shane Ernst
A recent benchmarking report on pharmaceutical manufacturing raises questions about the performance of contract manufacturers, but further analysis also raises concerns about the process and data used to arrive at this conclusion.
Guest Editorial
Public Comment and Expert Oversight: The Cornerstones of USP Standards Development
By Todd L. Cecil
USP exercises a vigorous standards-setting process that draws on both public comments and meticulous scientific review.
Agent-In-Place
Falling to Pieces
By Control, a senior compliance officer
Breaking up is easy to do.
In the Field
May 2007
Sanofi to Close Irish Plant, FDA Inspections and Warning Letters Continue to Decline, FDA Submits Final Proposals for PDUFA IV, and more.

ADVERTISEMENT
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
19%
To all process for new products only
14%
To select process for new products only
24%
To select processes for both new and legacy products
19%
Do not use QbD
24%
View Results
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FindPharma Custom Search
Featured Jobs

More Jobs
Click here